Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial.

Discussion In the present study, azilsartan showed a trend toward improvement in LV diastolic dysfunction in patients with either HFmrEF or HFpEF compared with candesartan, although the difference was not statistically significant (P = 0.057); azilsartan decreased LV E/e′ by 0.8, whereas candesartan increased it by 0.2 for 48 weeks, despite no significant differences in the time course of BP during 48 weeks between both groups.

also in 53,322 other papers